BioSpace News Archive

ABM Therapeutics, a clinical-stage biopharmaceutical company, today announced that the first patient has been successfully dosed in its multicenter Phase I study of ABM-1310 in patients with relapsed and drug resistant primary malignant brain tumors in China. This is the second clinical study of ABM-1310 in China.

Florida Cancer Specialists & Research Institute, LLC Is pleased to announce that Central Florida Cancer Care Center/Radiation Oncology Consultants, PA has joined the statewide practice, effective September 1, 2023.

Umoja Biopharma, Inc. today announced new data from an ongoing non-human primate (NHP) study demonstrating effective, durable, and well tolerated in vivo chimeric antigen receptor (CAR) T cell generation using the Company’s VivoVec™ platform technology at the 8th CAR-TCR Summit taking place in Boston, MA, August 29 - September 1, 2023.

Alliance for Multispecialty Research (AMR), a leading integrated research site organization, announced the appointment of Kari L. Delahunty as the Company’s first Chief Operating Officer.

For decades, many scientists have described the blood-brain barrier—a tight network of cells that separates the brain from the blood—as a nearly impenetrable border wall. But Andrew C. Yang, PhD, who is joining Gladstone Institutes as an assistant investigator, thinks there’s more to it than that.

ANGUS Chemical Company announced the completion of its corporate rebrand and corporate name change to Advancion Corporation, effective September 1, 2023.

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that it raised approximately $35 million through the exercise of all the Tranche A warrants issued as part the previously announced March 29, 2023 Private Investment in Public Equity (PIPE) financing.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today issued the following statement about the closure of COBRA, a minimum residual disease (MRD) study.

Immunocore Holdings Plc announced that management will present at the following investor conferences in September.